in-lin triplerx nda file partner crispr data
vertex report total cf revenu million slightli street consensu
million symdeko sale preliminari symkevi sale germani drove
upsid could see reacceler sale base expect
symdeko symkevi approv treat adolesc year vertex file
best triplerx regimen treat cf patient project total cf
sale grow billion year driven symdeko billion
triplerx launch vertex expand beyond cf announc track design
treat defici importantli partner crispr crsp ow dose
first beta-thalassemia patient therapi transform phase
data link reiter overweight trim price target
due market condit
cf sale grow total cf sale million compris kalydeco
million orkambi million symdeko/symkevi million
symdeko/symkevi launch drove beat initi sale germani expect
approv symdeko/symkevi younger patient age year drive
cf sale growth vertex maintain cf sale guidanc
billion continu forecast billion
triplerx growth ex-u reimburs question posit phase
triplerx data next-gen corrector link link appear
compar improv homozyg
improv het/min patient vertex wait full data
decid triplerx regimen file nda ou
highli confid european approv next year howev
high price vertex cftr modul present reimburs risk europ uk
franc latin america uk second highest preval cf patient
offer signific market opportun project total cf sale grow billion
cf beyond first beta-thalassemia patient engraft phase
i/ii studi patient data like potenti offer cure vertex
also work crispr cf therapi partner ow
develop cf mrna therapi address remain cf patient beyond cf
vertex advanc novel small molecul phase studi orphan diseas
aatd earn track design
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
reiter overweight rate trim price target
revis estim lower multipl increas cf sale estim
appli price-to-earnings multipl non-gaap dilut ep discount back
prior appli multipl non-gaap dilut ep discount
back higher non-gaap dilut ep primarili due higher
project cf sale return multipl multipl base market
condit roll discount period
rate apr close overweight price target base project
ev cash risk mrna therapeut novel could fail clinic
gain approv drug may reach sale forecast compani may
invest project
rate crsp apr close overweight price target base project
ev net cash risk technolog unproven may fail
man crispr involv patent litig could advers effect compani abil
conduct busi compani like requir futur capit
page
good sold
thousand except per share data
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found
